[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112023016298A2 - Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metóxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptafano-74-carboxamida - Google Patents

Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metóxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptafano-74-carboxamida

Info

Publication number
BR112023016298A2
BR112023016298A2 BR112023016298A BR112023016298A BR112023016298A2 BR 112023016298 A2 BR112023016298 A2 BR 112023016298A2 BR 112023016298 A BR112023016298 A BR 112023016298A BR 112023016298 A BR112023016298 A BR 112023016298A BR 112023016298 A2 BR112023016298 A2 BR 112023016298A2
Authority
BR
Brazil
Prior art keywords
dibenzene
aza
dioxo
carboxamide
fluoro
Prior art date
Application number
BR112023016298A
Other languages
English (en)
Inventor
Britta Olenik
Franco Rubino
Guillaume Levilain
Krischan Ziem
Michal Sowa
Susanne Röhrig
Tia Jacobs
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR112023016298A2 publication Critical patent/BR112023016298A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

agonistas de receptores de glicocorticoides substituídos por carbóx. a presente invenção refere-se a formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metóxi-32,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3 triazola-2(1,2),7(1)-dibenzena-heptafano-74-carboxamida que são a modificação cristalina i e a modificação cristalina ii, aos processos para sua preparação, às composições farmacêuticas que as compreendem e ao seu uso no controle de distúrbios.
BR112023016298A 2021-03-09 2022-03-04 Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metóxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptafano-74-carboxamida BR112023016298A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21161489 2021-03-09
PCT/EP2022/055521 WO2022189279A1 (en) 2021-03-09 2022-03-04 Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-5 dibenzenaheptaphane-74-carboxamide

Publications (1)

Publication Number Publication Date
BR112023016298A2 true BR112023016298A2 (pt) 2023-10-03

Family

ID=74867465

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023016298A BR112023016298A2 (pt) 2021-03-09 2022-03-04 Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metóxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptafano-74-carboxamida

Country Status (15)

Country Link
US (1) US20240174633A1 (pt)
EP (1) EP4304714A1 (pt)
JP (1) JP2024508971A (pt)
KR (1) KR20230155505A (pt)
CN (1) CN117015535A (pt)
AU (1) AU2022235150A1 (pt)
BR (1) BR112023016298A2 (pt)
CA (1) CA3212645A1 (pt)
CL (1) CL2023002676A1 (pt)
CO (1) CO2023011801A2 (pt)
DO (1) DOP2023000170A (pt)
IL (1) IL305231A (pt)
MX (1) MX2023010614A (pt)
TW (1) TW202302561A (pt)
WO (1) WO2022189279A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10081617B2 (en) 2015-04-16 2018-09-25 Merck Sharp & Dohme Corp. Factor XIa inhibitors
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
LT3765452T (lt) 2018-03-15 2022-05-25 Bayer Aktiengesellschaft Dviejų 4-{[(2s)-2-{4-[5-chlor-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2- oksopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamido darinių gavimo būdas
EP3898611A1 (en) * 2018-12-17 2021-10-27 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
AR117435A1 (es) 2018-12-21 2021-08-04 Bayer Ag Derivados de oxopiridina sustituidos

Also Published As

Publication number Publication date
MX2023010614A (es) 2023-09-19
KR20230155505A (ko) 2023-11-10
TW202302561A (zh) 2023-01-16
JP2024508971A (ja) 2024-02-28
WO2022189279A1 (en) 2022-09-15
CL2023002676A1 (es) 2024-02-09
IL305231A (en) 2023-10-01
CA3212645A1 (en) 2022-09-15
CN117015535A (zh) 2023-11-07
EP4304714A1 (en) 2024-01-17
DOP2023000170A (es) 2023-09-29
AU2022235150A1 (en) 2023-08-31
CO2023011801A2 (es) 2023-09-18
US20240174633A1 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
BR112022024943A2 (pt) Composição oral efervescente compreendendo um ingrediente ativo
BR112021022796A2 (pt) Inibidores de inflamassoma de nlrp3
BR112022007380A2 (pt) Composto bifuncional, e, composição
BRPI0713443A2 (pt) Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos
BR112017026704A2 (pt) uso
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
CR20200554A (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
BR112023016298A2 (pt) Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metóxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptafano-74-carboxamida
SV2018005776A (es) Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxamida
BR112014011333A2 (pt) derivados de pregenen-11ss-17-21-triol-3,20-diona para o tratamento de condições oculares
BR112021024938A2 (pt) Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
BR112022000490A2 (pt) Composição farmacêutica
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
BR112015028235A2 (pt) (ciano-dimetil-metil)-isoxazóis e -[1,3,4]tiadiazóis
CL2023001220A1 (es) Inhibidores de interleucina-17
BR112019000736A2 (pt) processo para preparação de composições de imunoglobulina
PT119473A (pt) Composição sólida de misturas inseticidas, processo para sua preparação e respetivas utilizações
BR112022003443A2 (pt) Processo de preparação de composição de mistura asfáltica, composição de mistura asfáltica, uso de uma composição de mistura asfáltica
BR112018014525A2 (pt) compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos
BR112013025906A2 (pt) "preparação farmacêutica compreendendo anticorpos imunoglobulina y ou seus fragmentos, e seu uso".
BR112021014406A2 (pt) Derivados de tiazolopiridina como antagonistas de receptor de adenosina
BR112021009078A8 (pt) Antagonistas substituídos de receptor de adenosina de aminotriazolopirimidina e aminotriazolopirazina, composições farmacêuticas e seus usos
BR112017028639A2 (pt) composto novo que se liga especificamente ao receptor ampa, composição farmacêutica e método para a produção do mesmo
BR112023005980A2 (pt) Anticorpos cd1a e seus usos
BR112022014278A2 (pt) Conjugados de composto proteico-antiviral